Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
29/11/2024 23:10
Nov 29 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS INC - RECEIVES DELIST LETTER FROM
NASDAQ
UNDER NASDAQ LISTING RULE 5550(B)(1)
Source text: ID:n0001104659-24-124081
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary